Table 3 TSQM and MMAS-8 compliance scores for the three groups after 12 months of treatment(M,Q1, Q3).

From: Safety and efficacy of one-dose nocturnal levetiracetam for the treatment of self-limited epilepsy with centrotemporal spikes: a randomized clinical trial

Group

TSQM efficacy satisfaction score

TSQM side effects satisfaction score

TSQM convenience satisfaction score

TSQM overall satisfaction score

Compliance (scores)

Group A(n = 65)

75(66, 75)*△

83(83, 100)*

83(83, 83)*

83(83, 83)*

7.3(6.5, 7.5)*

Group B(n = 62)

75(66, 83)#△

83(83, 100)#

88(83, 91)#

83(83, 91)#

7.5(7.1, 7.8)#

Group C(n = 65)

66(66, 66)*#

75(66, 91)*#

61(50, 83)*#

66(66, 75)*#

5.5(5.3, 6.5)*#

H

39.013

33.990

87.858

63.744

73.894

P

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

  1. *P<0.05 group C versus group A; #P<0.05 group C versus group B; △P<0.05 group A versus group B.
Back to article page